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We studied the presence of lymphangiogenesis in lymph node (LN) metastases of breast cancer. Lymph vessels were present in 52 of
61 (85.2%) metastatically involved LNs vs 26 of 104 (25.0%) uninvolved LNs (Po0.001). Furthermore, median intra- and perinodal
lymphatic endothelial cell proliferation fractions were higher in metastatically involved LNs (Po0.001). This is the first report
demonstrating lymphangiogenesis in LN metastases of cancer in general and breast cancer in particular.
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Lymph node (LN) status is the most important prognostic factor
for patients with breast cancer. The presence and the extent of
axillary LN metastases reflect the probability that the cancerous
process has spread through the body and both are strongly
correlated with the development of distant metastases and with
shortened disease-free and overall survival. Lymph node meta-
stases are more than passive tumour deposits. Metastatic tumour
sites are capable of inducing a vascular stroma and can actively
contribute to tumour progression and to further metastatic spread.
To what extent processes involved in progression of primary
tumours, such as angiogenesis and lymphangiogenesis, contribute
to progression of secondary sites is largely unknown. Reports have
suggested differences between primary tumours and secondary
sites and between different secondary sites. Whereas primary
breast tumours grow angiogenesis dependently, we demonstrated
that 90% of breast cancer liver metastases grow according to an
angiogenesis-independent replacement pattern (Stessels et al,
2004). The growth of breast cancer LN metastases, on the contrary,
was angiogenesis dependent and angiogenesis and hypoxia in the
metastases were correlated with angiogenesis and hypoxia in the
primary tumours (Van den Eynden et al, 2005). Guidi et al (2000)
demonstrated that the presence of vascular hot spots in LN
metastases, but not in the primary breast tumours was associated
with decreased survival.
In the present study, we compared the expression of the
lymphatic endothelium-specific markers Prox-1, LYVE-1 and
podoplanin in metastatically involved and uninvolved LNs of
patients with breast cancer. Prox-1 and LYVE-1 are, respectively, a
transcription factor and a hyaluronan receptor that show
specificity for lymphatic endothelial cells. D2-40 was originally
described as a selective monoclonal antibody to a Mr 40000
O-linked sialoglycoprotein that reacts with a fixation-resistant
epitope in lymphatic endothelium (Kahn and Marks, 2002).
Recently, the D2-40 antibody has been shown to specifically
recognise podoplanin, a glomerular podocyte membrane protein
(Schacht et al, 2005) and has been shown to be a very sensitive and
specific marker for lymphatic endothelium in most tissues
(Evangelou et al, 2005) and especially in breast cancer (Van der
Auwera et al, 2005). We investigated the presence and extent of
lymphangiogenesis in LN metastases of breast cancer using the
podoplanin antibody.
MATERIALS AND METHODS
Patients and samples
One hundred and ten patients with operable breast cancer were
included in this study, 49 patients with LN-negative and 61
patients with LN-positive breast cancer. Clinico-pathological
features are compared between both study groups in Table 1,
using the UICC TNM system. Formalin-fixed paraffin-embedded
tissue blocks of one metastatically involved and – if available – one
uninvolved LN of patients with LN-positive breast cancer and one
metastatically uninvolved LN of patients with LN-negative breast
cancer were selected for immunohistochemical examination. Of six
LN-positive patients, no uninvolved LN was available.
Expression of lymphatic endothelium-specific and vascular
markers
Immunohistochemical stainings for the lymphatic endothelium-
specific markers podoplanin (clone D2-40, Dako, Glo ¨strup,
Denmark), Prox-1 (polyclonal, Reliatech, Braunschweig, Germany)
and LYVE-1 (polyclonal, Reliatech) and for the panendothelial
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smarkers CD34 (clone QBEnd10, Dako) and CD31 (clone JC70A,
Dako) were performed on serial sections of a subset (n¼20) of
metastatically involved and uninvolved LNs. A detailed description
of the protocol of these stainings has been published before (Van
der Auwera et al, 2005) (Figure 1).
Presence of lymph vessels and lymphangiogenesis
An immunohistochemical staining for podoplanin (clone D2-40,
Dako) and an immunohistochemical double staining with anti-
podoplanin (clone D2-40, Dako) and anti-Ki-67 antibodies (clone
MIB-1, Dako) were performed on sections of all included cases.
The presence of lymph vessels (LVs) was assessed intranodally
(within the LN capsule) of metastatically involved and uninvolved
LNs, and, if LVs were present, intranodal lymphatic endothelial
cell proliferation fraction (LECP%) was assessed by counting Ki-67
positive and negative lymphatic endothelial cells. If perinodal LVs
were present, perinodal LECP% was also assessed. Only cases with
410 lymphatic endothelial cells were included for statistical
analysis.
Statistical analysis
Statistical analyses were performed with the SPSS 13.0 software
package. A P-value o0.05 was considered statistically significant.
Correlations between categorical variables (e.g. presence of LVs,
metastatical involvement) were analysed using a w
2 test. LECP% in
different groups was compared with a Kruskal–Wallis nonpara-
metric test.
RESULTS
Results of the comparison of the expression of the different
vascular markers in and around metastatically uninvolved LNs of
patients with breast cancer are shown in Table 2. Although the
littoral cells of the marginal and trabecular sinuses were very
focally and faintly immunoreactive for podoplanin, no intranodal
podoplanin immunoreactive vascular structures were demon-
strated except in trabecular septa or areas of lipomatosis and
fibrosis (Figure 1A–F). In contrast, in most metastatically involved
LNs vascular structures staining for podoplanin were observed.
These structures were also positive for Prox-1, CD31 and CD34.
They were only faintly LYVE-1 positive or did not show LYVE-1
immunoreactivity (Figure 1G–K).
We then analysed the presence of LVs in the total study
population, using podoplanin as a lymphatic marker. Lymph
vessels were only seen in 26 out of 104 (25.0%) uninvolved LNs. In
22 of these 26 (84.6%) LNs, LVs were seen in areas of lipomatosis
or fibrosis or in trabecular septa. There was no difference in the
presence of LVs in uninvolved LNs of patients with LN-negative
and LN-positive breast cancer (P¼0.91). In contrast, LVs were
demonstrated in 52 of 61 (85.2%) metastatically involved LNs
(Po0.001) (Table 3). These LVs were often localised at the
metastasis/LN interface or in the LN parenchyma close to the
metastasis.
Figure 2 shows Box and Whisker’s plots comparing intranodal
(Figure 2A) and perinodal (Figure 2B) LECP% in all groups. The
median intranodal LECP% was 6.0% (n¼42) in metastatically
involved LNs compared to 1.6% (n¼11) in uninvolved LNs of
LN-negative and 0.0% in uninvolved LNs (n¼9) of LN-positive
patients (Po0.001). The median perinodal LECP%s were 2.9, 0.0
and 0.0% in metastatically involved LNs (n¼25), uninvolved LNs
from LN-positive patients (n¼37) and in uninvolved LNs from
LN-negative patients (n¼20), respectively (Po0.001).
DISCUSSION
To the best of our knowledge, this is the first report demonstrating
the presence of lymphangiogenesis in secondary sites of human
cancer in general and in LN metastases of breast cancer in
particular. First, different lymphatic endothelial-specific markers
were compared. As LYVE-1 reactivity of LVs close to LN
metastases decreases, as LYVE-1 reactivity of macrophages and
intravascular proteins in both blood and LVs hampers interpreta-
tion (see Figure 1) and as Prox-1 is a nuclear antigen, we preferred
to use podoplanin (clone D2-40) to study the presence of LVs and
lymphangiogenesis in the total study population. In a previous
study, we have shown that although LYVE-1 expression on LVs
located at the tumour periphery was strong, no or weak
immunoreactivity was found in intratumoral LVs and that
podoplanin is the best marker to visualise LVs in and around
primary breast tumours (Van der Auwera et al, 2005).
In primary human tumours, the contribution of lymphangio-
genesis vs lymphatic cooption and the functionality of tumour
lymphatics are still controversial. Nevertheless, LVs containing
proliferating nuclei have been observed in breast cancer (Van der
Auwera et al, 2005), endometrial cancer (Koukourakis et al, 2005),
head and neck cancer (Beasley et al, 2002) and melanoma (Dadras
et al, 2003; Straume et al, 2003). As LVs were only found in a
minority of uninvolved axillary LNs, the increase of the presence of
LVs in metastatically involved LNs is likely to be due to
lymphangiogenesis. An increased LECP% was indeed found in
and around metastatically involved LNs. Although misinterpreta-
tion of nuclei from proliferating tumour cells penetrating the
vessel wall or underlying the LV as endothelial cell nuclei might
lead to falsely elevated LECP%, careful interpretation by experi-
enced investigators can largely reduce this bias. Tumour cell nuclei
and endothelial cell nuclei mostly differ from shape and the use of
Table 1 Comparison of clinico-pathological variables of the primary
tumour in N0 and N+ patients included
N0 (n¼49) N+ (n¼61) P-value
Mean age (range) 60.9 (34.3–85.4) 59.6 (25.3–84.4) 0.63
Histology 0.81
IDA 40 48
ILA 6 10
Other 3 3
T status 0.004
T1 28 15
T2 18 37
T3 2 5
T4 1 4
N status NA
N0 49 0
N1 0 27
N2 0 20
N3 0 14
ER 0.78
Negative 14 16
Positive 35 45
PR 0.26
Negative 18 29
Positive 31 32
Her-2/neu 0.6
Negative 42 50
Positive 7 11
ER¼oestrogen receptor; IDA¼infiltrating ductal adenocarcinoma; ILA¼infiltrating
lobular adenocarcinoma; N0¼lymph node negative, N+¼lymph node positive;
PR¼progesteron receptor. Age, histological type, T and N status, ER and PR status,
HER-2/neu oncoprotein status were recorded by review of the pathology files. In N+
patients, tumours were larger than in N0 patients.
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smicroscopy at different focal planes further reduces this bias. The
methodology adopted in this study to measure ECP% is widely
accepted in the angiogenesis field (Vermeulen et al, 2002) and has
recently been introduced in the lymphangiogenesis field (Dadras
et al, 2003; Beasley et al, 2002; Straume et al, 2003; Koukourakis
et al, 2005; Van der Auwera et al, 2005). The median intranodal
LECP% of 6.0% suggests that lymphangiogenesis in metastatically
involved LNs is higher than in primary breast tumours: we
previously demonstrated that LECP% in primary breast tumours
was 1.83% (Van der Auwera et al, 2005).
Our results corroborate the concept of LN lymphangiogenesis,
which was recently introduced and shown to be involved in the
recruitment of dendritic cells to inflamed LNs (Angeli et al, 2006).
The authors demonstrated that the lymphangiogenic response in
the LNs was particularly localised in the subcapsular space and
around B-cell follicles from where LVs penetrated into the cortex.
Whether the outgrowth of new LVs in metastatically involved
axillary LNs originates from the subcapsular marginal sinus or
from LVs in areas of lipomatosis or in fibrous septa remains to be
elucidated.
Different hypotheses could be raised about the role of LN
lymphangiogenesis in metastatically involved LNs. On the one
hand, LN lymphangiogenesis might be part of the immunological
reaction against the tumour cells and on the other hand be
involved in tumour progression and metastases, as in primary
tumours. Therefore, LN lymphangiogenesis, as LN angiogenesis,
might contribute to the metastatic spread of breast cancer. In a
transgenic mouse model of skin cancer, Hirakawa et al (2005)
demonstrated that the induction of lymphangiogenesis by vascular
endothelial growth factor A is involved in tumour progression.
They furthermore showed that VEGF-A also induces lymphangio-
genesis in the sentinel LN and that lymphangiogenesis is induced
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Figure 1 Overview of the immunohistochemical stains used on serial sections of a metastatically uninvolved (perinodal fat: A–B; LN: C–F) and involved
LN (G–L). In uninvolved LNs, high endothelial venules (*) show CD34 (C) and CD31 (D) reactivity. Littoral cells (þ) are positive for CD31 (D) and Prox-
1( F). In metastatically involved LNs, podoplanin-positive LVs (red arrow) are demonstrated (G). Blood vessels (yellow arrow) are podoplanin negative (G).
The LVs show CD34 (J), CD31 (K) and Prox-1 (I) reactivity. Although in perinodal fat (B) LVs are strongly positive for LYVE-1, the LVs in metastatically
involved LNs are only faintly positive for LYVE-1 (H). Furthermore, a proliferating lymphatic endothelial cell is shown at the border of a LN metastasis (L)
(LN: lymph node; LV: lymph vessel).
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sbefore metastasising (Hirakawa et al, 2005). Based on our data, it is
difficult to investigate the mutual contribution of local and remote
mechanisms to the induction of lymphangiogenesis in LNs of
patient with breast cancer. However, the difference in LECP% in
uninvolved LNs of patients with N0 vs Nþ breast cancer is
intriguing in this context.
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Figure 2 Comparison of intranodal (A) and perinodal (B) LECP%
between metastatically involved and uninvolved axillary LNs in patients
with LN-negative and LN-positive breast cancer. Both intra- (Po0.001)
and perinodal (Po0.001) LECP% is significantly increased in metastatically
involved LNs compared to uninvolved LNs (LECP%: lymphatic endothelial
cell proliferation fraction; LN: lymph node; N0: lymph node negative; Nþ:
lymph node positive).
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